BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Avedro, Inc. Announces CE Approval for Lasik Xtra™


1/4/2012 6:43:35 AM

WALTHAM, Mass.--(BUSINESS WIRE)-- Avedro, Inc. announced today that the Company’s proprietary Lasik Xtra procedure has received CE Approval. Lasik Xtra is a two minute procedure used in conjunction with standard Lasik to restore the biomechanical integrity and strength to the cornea after a Lasik procedure. Lasik Xtra has been successfully used in thousands of Lasik surgeries outside the US.

“Cross-linking within a LASIK procedure using Lasik Xtra is simple, fast and safe,” said A. John Kanellopoulos, MD, a leading refractive surgeon and member of Avedro’s Medical Advisory Board. “In studies we’ll be reporting at ASCRS in April we’ve found that after almost two years of follow-up, hyperopes appear to have a completely different clinical course if we employ prophylactic cross-linking in their LASIK procedures. Hyperopic LASIK typically regresses more than myopic LASIK.”

Lasik Xtra combines VibeX™ (riboflavin ophthalmic solution) with its KXL™ System (UVA irradiation) to achieve accelerated corneal cross-linking during a Lasik procedure. "Avedro has the only cross-linking products specifically CE approved for performing Lasik Xtra and we are pleased to offer those products to a growing number of ophthalmologists and their Lasik patients outside the US,” said David Muller, CEO of Avedro.

About Avedro, Inc.

Avedro is a privately held medical device and pharmaceutical company advancing the science and technology of corneal cross-linking. Avedro recently completed its US-based, multi-centered, Phase III studies of corneal cross-linking for the treatment of progressive keratoconus and corneal ectasia following refractive surgery. Outside the United States, Avedro has commercialized both VibeX and its KXL System for performing Lasik Xtra and accelerated cross-linking. Additionally, Avedro is developing the science of Thermo-biomechanics for therapeutic medical applications. The Keraflex® refractive correction procedure is the first technology developed from the Thermo-biomechanics platform and is a non-invasive, incision-less ophthalmic procedure for flattening the cornea without the removal of tissue. Keraflex offers the unique ability to induce refractive change without weakening the cornea’s biomechanical integrity, as happens with Lasik and other refractive correction procedures. Keraflex is commercially available outside of the United States.

Contact:

Avedro, Inc.

Kristen Gleason, 781-768-3400

kgleason@avedro.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES